A detailed history of Pavion Blue Capital, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Pavion Blue Capital, LLC holds 8,684 shares of ABBV stock, worth $1.68 Million. This represents 0.74% of its overall portfolio holdings.

Number of Shares
8,684
Previous 8,684 -0.0%
Holding current value
$1.68 Million
Previous $1.58 Million 5.82%
% of portfolio
0.74%
Previous 0.79%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 02, 2023

BUY
$132.51 - $164.9 $29,152 - $36,278
220 Added 2.6%
8,684 $1.17 Million
Q4 2022

Feb 07, 2023

BUY
$138.31 - $165.87 $41,493 - $49,761
300 Added 3.67%
8,464 $1.37 Million
Q3 2022

Nov 03, 2022

BUY
$134.21 - $153.93 $13,421 - $15,393
100 Added 1.24%
8,164 $1.1 Million
Q2 2022

Aug 02, 2022

BUY
$137.62 - $174.96 $2,064 - $2,624
15 Added 0.19%
8,064 $1.24 Million
Q1 2022

May 05, 2022

BUY
$131.98 - $163.75 $39,594 - $49,125
300 Added 3.87%
8,049 $1.31 Million
Q4 2021

Jan 28, 2022

BUY
$107.43 - $135.93 $96,687 - $122,337
900 Added 13.14%
7,749 $1.05 Million
Q4 2021

Jan 26, 2022

SELL
$107.43 - $135.93 $124,511 - $157,542
-1,159 Reduced 14.47%
6,849 $927,000
Q3 2021

Nov 16, 2021

BUY
$106.4 - $120.78 $95,760 - $108,702
900 Added 12.66%
8,008 $864,000
Q3 2021

Nov 12, 2021

SELL
$106.4 - $120.78 $95,760 - $108,702
-900 Reduced 11.24%
7,108 $767,000
Q2 2021

Aug 10, 2021

SELL
$105.21 - $117.21 $52,605 - $58,605
-500 Reduced 5.88%
8,008 $902,000
Q1 2021

May 10, 2021

SELL
$102.3 - $112.62 $4,398 - $4,842
-43 Reduced 0.5%
8,508 $921,000
Q2 2020

Aug 06, 2020

BUY
$73.37 - $98.18 $5,869 - $7,854
80 Added 0.94%
8,551 $840,000
Q1 2020

May 11, 2020

BUY
$64.5 - $97.79 $231,426 - $350,870
3,588 Added 73.48%
8,471 $645,000
Q4 2019

Jan 30, 2020

BUY
$72.13 - $90.25 $352,210 - $440,690
4,883 New
4,883 $432,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $342B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Pavion Blue Capital, LLC Portfolio

Follow Pavion Blue Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pavion Blue Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pavion Blue Capital, LLC with notifications on news.